4SCAR22

4SCAR22 is a fourth-generation chimeric antigen receptor T-cell (CAR-T) therapy targeting the CD22 antigen, developed by the Shenzhen Geno-Immune Medical Institute. It is primarily designed for the treatment of relapsed or refractory B-cell malignancies, including cases where patients have developed CD19-negative disease following CD19-targeted therapies. The CAR construct is delivered via a lentiviral vector and features a complex intracellular signaling domain comprising CD28, CD27, and CD3ζ, along with an inducible Caspase 9 (iCasp9) safety switch. This safety switch allows for the selective elimination of the CAR-T cells in the event of severe toxicity, such as cytokine release syndrome. In clinical settings, 4SCAR22 is frequently evaluated as part of a multi-target or sequential CAR-T approach, often in combination with 4SCAR19 (targeting CD19) to mitigate antigen escape and improve therapeutic durability.

Other names

4th generation CD22-targeting CAR-T cellsCD22-specific CAR-T cells with iCasp9CD-22-specific CAR-T cells with iCasp9CD 22-specific CAR-T cells with iCasp9